ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed. After completing initial research, the Company is pursuing clinical trials and FDA regulatory approval of Nanoveson(TM) as a prescription drug treatment for non-alcoholic fatty liver disease (NAFLD).
Over 60 million adult Americans suffer from NAFLD and these numbers are rising rapidly. There is no FDA approved NAFLD treatment. NAFLD is a global health crisis. NAFLD is also associated with the metabolic syndrome and other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer.
Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases and comorbid diseases utilizing the principles of Applied Lipid Polymorphism, which includes a revolutionary application of nanobiotechnology in the area of self-organizing lipid membranes. Nanoveson(TM) therapy utilizes only natural compounds. The therapy triggers liver triglyceride remodeling into bile phospholipids and lipid membrane fusion and aggregation in the intestines.
Molecular compounds including biliary phospholipids, arachidonic acid metabolites, cholesterol, methyl metabolites, phthalate esters, and other compounds sequestered in vesicle membranes are expected to be a rich source of disease state biomarkers. Nanoveson(TM) also has the potential to provide extensive support to the life sciences industry in the area of drug metabolism testing.
Research has demonstrated that enterohepatic circulation is the mechanism that maintains quantitative whole body homeostasis of arachidonic acid. There is extensive research focused on blocking arachidonic acid metabolism along cytochrome P450, leukotriene, prostaglandin, and thromboxane eicosanoid pathways. Arachidonic acid metabolism is implicated in many inflammatory diseases, including cardiovascular diseases, gastrointestinal diseases, arthritis, asthma, diabetes and cancer.
Nanoveson(TM) therapy may improve enterohepatic circulation by removing excess triglyceride deposits in the liver and improving bile flow; having a positive therapeutic impact on arachidonic acid driven disease states by reducing arachidonic acid availability for inflammatory metabolism. Orphan disease indication targets for inflammatory diseases may be pursed through clinical trials focused on arachidonic acid specific surrogate end points.
David K. Barker, Founder and CEO of ALP Life Sciences, LLC stated, “The preliminary evidence for the Nanoveson(TM) hypotheses is very promising, however, it should be emphasized that the complex mechanisms of action triggered by Nanoveson(TM) must be quantified, and the efficacy for targeted indications must be established by clinical trials.” Barker added, “I’d like to take this opportunity to acknowledge the many scientists and physicians referenced in the Nanoveson(TM) whitepaper. Without their dedication to medical research the preliminary research and hypotheses presented in the Nanoveson(TM) whitepaper would not have been possible. However, nothing in this release or in the whitepaper suggests referenced researchers endorse the preliminary conclusions presented at this time.”
ALP Life Sciences, LLC is a life sciences research and development company focused on therapeutics and diagnostics based on the new and emerging science of Applied Lipid Polymorphism. ALP Life Sciences, LLC is currently evaluating strategic relationships in the area of principal investigators, clinical trial facilities, medical school research partnerships, manufacturing, commercialization, global licensing and partnering opportunities for therapy, diagnostics and drug metabolism testing. Relationships with medical research foundations, public institutes of health, and life sciences venture capital firms are also being evaluated. Interested parties should contact ALP Life Sciences, LLC.